Pentadeca Arginate (PDA): Evidence, Legal Status and Risks

Quick answers

What is it?: A product sold as BPC-157, a lab-made chain of 15 amino acids, in a salt form made with the amino acid arginine¹⁴. Clinics and pharmacies market it as a more stable BPC-157 for injury and gut healing¹¹⁹. It is not an approved medicine⁵.
Does it work?: Unknown. We found no published study of it in people³⁶. Its only data are the patent holder’s own 2017 animal and lab results, not peer reviewed⁴. Human studies of BPC-157 do not count: they did not name the salt form, and salts can behave differently⁷⁸.
Is it safe?: Unknown: we found no published study of it in people³⁶. Its patent says rats given a high dose showed no toxicity, but PubMed lists no study that has checked this³⁴. FDA says compounded BPC-157 may trigger immune reactions by some routes⁹.
Is it legal?: Not approved⁵. By our reading, US pharmacies may not make it, though some sell it¹¹⁰¹¹. Australia’s rules for BPC-157 cover its salts: prescription only, and illegal to hold without one¹². Banned in sport as BPC-157¹³²⁶.
What is in the vials?: Unknown. Finnrick, a testing service, had published 11,999 tests of 34 products by 25 September 2026, none of them PDA¹⁴. In a 2024 doping case, a lab found BPC-157 and an unlisted banned substance in capsules labeled as containing BPC-157 arginate salt²⁶.

What it is

Pentadeca arginate, or PDA, is the name clinics and compounding pharmacies use for BPC-157 sold as an arginine salt: the same 15-amino-acid peptide, paired with the amino acid arginine instead of acetate¹²¹⁵. BPC-157 is a lab-made peptide that FDA describes as a fragment of a protein originally isolated from human gastric juice⁷; see our BPC-157 entry. FDA treats the free base (the peptide alone) and the acetate salt as different ingredients, and says salts of one molecule can differ in stability, solubility and toxicity⁷⁸. A 2017 US patent describes arginine salts of the peptide and prefers one with two arginine molecules per peptide, which it calls Arg-BPC⁴. Sellers say the arginine makes it more stable, including in stomach acid, so that it suits oral use¹¹⁶. How BPC-157 itself works is not known: FDA says its molecular targets have not been identified⁷. One clinic claims the arginine also raises nitric oxide, a signal that widens blood vessels; we found no study testing that for PDA³¹⁶.

The arginine salts were patented by Diagen, a company in Ljubljana, Slovenia, with Rudolf Rucman as inventor: the Slovenian filing dates from 13 March 2013, and the US patent was granted on 26 December 2017⁴. The patent calls its preferred compound ‘bepecin di-L-arginine salt (abbr.: Arg-BPC)’; bepecin is another name for BPC-157⁴¹⁷. BPC-157 itself was first made at the University of Zagreb, Croatia, in the early 1990s⁷. The patent says all its pharmacology experiments, which it describes partly ‘by citation of literature sources’, used the arginine salt, yet it also says that until then the peptide ‘has always been used either in a free form or in an acetate form or as a salt with bases such as sodium salt’⁴. A 2016 rat study from the Zagreb group names Diagen as the supplier of its BPC 157 without naming a salt form¹⁸, and FDA says most of the animal studies it reviewed do not identify the form used⁷. A clinic page first published on 31 July 2024 presents PDA as ‘a new version of BPC-157’ that was already ‘in development’ when BPC-157 was on a list of medicines to stop being compounded¹⁹.

Benefits: what the research shows

We found no published study of pentadeca arginate in people. PubMed lists no paper on it, and ClinicalTrials.gov lists no trial that names it (searches on 8 October 2026)³⁶. The only journal mention we found is a short passage in a 2026 review, which calls it ‘a stabilized form of BPC-157, designed to enhance bioavailability and shelf-life’ but cites no study of it²¹. Clinics and sellers agree: a sports-medicine clinic’s library page says ‘There are no controlled human trials of PDA, no established dosing and no long-term safety data’, and a telehealth seller says ‘no standardized human clinical data exist for PDA’²²⁰. The small human studies of BPC-157 do not count for the arginine salt: FDA says those papers ‘do not clearly identify BPC-157 as a free base or salt’, and that different salts ‘can have very different properties and toxicities’⁷⁸. Their results are in our BPC-157 entry. The only data on the salt itself come from the 2017 patent, which was not peer reviewed⁴. In the patent’s lab tests, the arginine salt broke down far more slowly than BPC-157 acetate: after 1 hour in water at 100 °C, its measured peptide content was 99.08% (99.05% at the start), while the acetate’s fell from 98.89% to 56.80%⁴. After 5 hours in artificial gastric juice at pH 3.0, 84.9% of the arginine salt remained, against 0.08% of the acetate⁴. In stronger acid (pH 2.0), little of either survived 2.5 hours: 4.9% of the arginine salt and 2.1% of the acetate⁴. The patent argues that better stability in gastric juice leaves the peptide available longer for absorption and activity, but it reports no absorption measurements⁴. For healing, it says that ‘by using the methods specifically described in literature’ it found that ‘bepecin markedly increases healing’ of cut ligaments, tendons, muscles and nerves and of broken bones, but it gives no figures, and it does not compare the arginine salt with the acetate in any animal test⁴. A 1995 report cited by FDA found BPC-157 resistant to breakdown in human gastric juice in the lab, unlike the acetate in the patent’s tests; FDA does not say which form that report used⁷. We grade the evidence tier D, animal data only: the patent says all its experiments used the arginine salt and names that salt in the text of two animal tests, an antiviral test in newborn mice and a toxicity test in rats, and we found no published human data³⁴.

Key human studies

No completed human studies were found.

Doses studied

Doses below are what studies used or what a label says. They are not advice, and gray-market products may not contain what their label says.

In human studies

PubMed lists no human study of pentadeca arginate, and ClinicalTrials.gov lists no trial that names it³⁶. A trial of tablets holding 1 mg of BPC-157 each, in healthy volunteers, was registered in 2015, but its record does not say which form of BPC-157 the tablets held, and no results have been posted⁷²⁵.

In animal studies

The patent says all its pharmacology experiments, in cells and animals, used the L-arginine salt⁴. Describing rat experiments on surgical adhesions, which it introduces with ‘Our previous research demonstrated’ and which follow methods published from 2007 to 2010, it says the peptide was used in its ‘regular low doses’ of 10 ng to 10 µg per kg of body weight, given by injection, by mouth or locally⁴. In an antiviral test in newborn mice, it says ‘Bepecin L-arginine salt was applied in doses of 10 µg/kg and 100 µg/kg’⁴. In an acute toxicity test, it says rats given 1 g/kg into the abdominal cavity, a vein or the stomach showed ‘no toxicity and no adverse effects’, and it gives no further details of that test⁴. These are animal research doses, not human doses.

What users report Anecdotal · not validated · not a recommendation

One community reference page lists about 250 to 500 µg per dose, once or twice a day, and says these figures are borrowed from BPC-157¹⁵.

Routes: Injection under the skin (offered by clinics, pharmacies and telehealth sellers; no human data found)
Injection into muscle (offered by some sellers; rat experiments in the patent; no human data found)
Oral capsules or liquid (offered by some sellers; lab and rat experiments in the patent; no human data found)
Injection into the abdominal cavity (animal experiments in the patent only)
Creams, gels, eye or nose drops, suppositories, enemas and skin patches (forms proposed in the patent; no human data found)

Every dose studied for Pentadeca arginate (PDA), with sources →

Legal status

United States: Not approved by FDA for any use: Drugs@FDA, FDA’s database of approved drugs, lists no product with pentadeca arginate, BPC-157 or bepecin as an ingredient (data updated 7 October 2026)⁵. FDA found no approved product containing BPC-157 in any country⁷. FDA’s 2026 review of BPC-157 for compounding covered only the free base and the acetate salt and does not mention an arginine salt of BPC-157⁷⁸. FDA says it has ‘encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name’⁷.
US pharmacies: Under section 503A of federal drug law, a pharmacy compounding for individual patients may use a bulk ingredient only if it meets a USP or NF monograph (an official quality standard), is a component of an FDA-approved drug, or is on FDA’s 503A bulks list¹¹. FDA found no monograph for BPC-157 or its acetate, and neither is in an approved drug⁷; no approved drug contains pentadeca arginate either⁵. No form of BPC-157 appears in any category of FDA’s list of nominated substances, updated 14 May 2026, and FDA says it does not intend to place substances nominated on or after 7 January 2025 into those categories¹⁰¹¹. FDA lists BPC-157 among compounding ingredients that may present significant safety risks, in its table of substances ‘previously in category 2’ that were ‘nominated but withdrawn’⁹. FDA’s documents do not mention an arginine salt of BPC-157⁷⁸, so this is our reading: US pharmacies may not compound pentadeca arginate under section 503A. On 23 July 2026, FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with 1 abstention, separately for the free base and for the acetate, to recommend adding BPC-157 to the bulks list²³; only those two forms were on the agenda²⁴. FDA told the committee that when a salt is listed, ‘only that particular salt or ester may be used’, and that other salts ‘must be evaluated for eligibility’⁸. FDA says any change would come through notice-and-comment rulemaking, and it had posted no minutes by 8 October 2026¹¹²³²⁴. A Las Vegas pharmacy that calls itself ‘a licensed 503A compounding pharmacy’ markets PDA capsules, liquid and injections¹.
Other countries: Australia: the Poisons Standard in force from 1 October 2026 does not name pentadeca arginate, but it says a reference to a substance includes ‘every salt’ of it, and it lists BPC-157 in Schedule 4 (prescription only) and in Appendix D clause 5, which makes possession without authority illegal¹². A BPC-157 arginine salt, which is what the patent and sellers describe, therefore falls under both rules¹⁴¹². Other countries: not verified.
Sport: Pentadeca arginate is not named on WADA’s (World Anti-Doping Agency) 2026 Prohibited List or on the 2027 List, which takes effect on 1 January 2027¹³²². Class S0 bans at all times any substance not covered elsewhere on the List ‘with no current approval by any governmental regulatory health authority for human therapeutic use’, and names BPC-157 as an example¹³. Pentadeca arginate is sold as an arginine salt of BPC-157¹⁴, and USADA, the US Anti-Doping Agency, has treated that salt as BPC-157: in 2024 it charged a US short track speed skater with using BPC-157 and DHEA after the athlete declared taking a supplement whose label listed ‘Body Protective Compound (as BPC-157 Arginate Salt)’²⁶. A WADA-accredited laboratory found both substances in the capsules, though DHEA was not on the label, and an arbitrator banned the athlete for one year²⁶. Even as a separate substance, it would fall under S0 by our reading: it is not approved in the US, and FDA found no approved BPC-157 product in any country⁵⁷. WADA has not ruled on pentadeca arginate by name. The 2027 List keeps this wording and adds ‘peptides’ to its examples²².

Pentadeca arginate (PDA) in the legal tracker →

Quality and the gray market

What testing finds

We found no independent test of a product sold as pentadeca arginate: Finnrick, a peptide-testing service, had published 11,999 tests of 34 products by 25 September 2026, and none was of pentadeca arginate¹⁴. The only independent analysis we found of a product labeled as this salt comes from a 2024 anti-doping case: a WADA-accredited laboratory found 200 and 290 µg of BPC-157 per capsule in an open and a sealed bottle of a supplement whose label listed ‘Body Protective Compound (as BPC-157 Arginate Salt)’, and it also found DHEA, a banned substance not on the label²⁶. Of the seller and clinic pages we read, one clinic page gives the formula of BPC-157 alone and the others give no formula; none states the salt ratio^12161920. FDA says it has encountered multiple salts and derivatives sold under the BPC-157 name⁷.

How it is sold

Pentadeca arginate is marketed by US compounding pharmacies, clinics and telehealth services^1161920. A Las Vegas pharmacy offers it as capsules or liquid for gut problems and as injections for joint, tendon and muscle injuries, and says ‘In essence, PDA is BPC-157’¹. In 2024, a clinic presented PDA as a new version of BPC-157 at a time when BPC-157 was on a list of medicines ‘to be stopped being compounded’¹⁹. Sellers say it is more stable and better absorbed than BPC-157¹⁶¹⁹; the only stability data we found are the patent’s lab tests, and we found no absorption data³⁴. A community reference page calls it ‘BPC-157 in arginate-salt form’ and says that what distinguishes it ‘is a marketing claim, not evidence’¹⁵. We found no data on how widely it is used, and Finnrick’s public test summary does not list it¹⁴.

Side effects and risks

Unknown human safety: we found no published study that gave pentadeca arginate to people, so its side effects and long-term effects are unknown³⁶. The only safety data on the salt that we found are a two-sentence report of acute toxicity tests in rats in its patent⁴.
Immune reactions: FDA says compounded BPC-157 ‘may pose risk for immunogenicity for certain routes of administration’ (triggering unwanted immune responses); we found no study of this for the arginine salt³⁹.
Cancer risk: we found no study of it in PubMed, and a 2026 review says PDA’s effect on blood vessel growth carries a theoretical risk of tumor growth in abnormal, precancerous tissue, a risk the authors call speculative³²¹.
Uncertain contents: we found no independent lab results for products sold as PDA, and none of the seller or clinic pages we read states the salt ratio^1214161920. In a 2024 doping case, capsules labeled as containing BPC-157 arginate salt also contained DHEA, a banned substance not on the label, and FDA has encountered different salts and derivatives sold under the BPC-157 name⁷²⁶.
Oral products may not deliver intact peptide: in the patent’s own test, only 4.9% of the arginine salt remained after 2.5 hours in artificial gastric juice at pH 2.0, and we found no study measuring its absorption³⁴.
Legal and anti-doping risk: by our reading US pharmacies may not compound it, Australia’s BPC-157 rules make possession without a prescription illegal, and sport bans it as BPC-157: in 2024 a US athlete was banned for a year over a supplement labeled as containing BPC-157 arginate salt, which also contained DHEA, another banned substance^10121326.

Questions people ask

Is pentadeca arginate the same as BPC-157?

It is sold as BPC-157 in a salt form: the same 15-amino-acid chain, paired with the amino acid arginine¹⁴. FDA treats each form of BPC-157 as a separate ingredient and says salts can differ in stability, solubility and toxicity, so data on one form do not automatically apply to another⁷⁸.

Is PDA more stable than BPC-157?

Partly, in lab tests reported in its patent, which was not peer reviewed: after 5 hours in artificial gastric juice at pH 3.0, 84.9% of the arginine salt remained against 0.08% of the acetate, but in stronger acid (pH 2.0) only 4.9% and 2.1% remained after 2.5 hours⁴. We found no study testing whether that makes a difference in animals or people³⁴. A 1995 report cited by FDA found BPC-157 itself resistant to breakdown in human gastric juice⁷.

Is pentadeca arginate FDA approved?

No. Drugs@FDA lists no product containing it, and FDA found no approved BPC-157 product in any country⁵⁷.

Can compounding pharmacies make pentadeca arginate?

By our reading, no. FDA’s 2026 review covered only the free base and the acetate salt, found no official quality standard (monograph) for either and no approved drug containing BPC-157, and FDA says each salt must be evaluated separately⁷⁸. No form of BPC-157 is in FDA’s interim categories for compounding, though at least one pharmacy markets PDA¹¹⁰.

Is pentadeca arginate safe?

Unknown: we found no published study of it in people³⁶. Its patent reports no toxicity in rats given 1 g/kg, but PubMed lists no study that has checked this³⁴. FDA says compounded BPC-157 may trigger immune reactions and that it ‘lacks sufficient information to know whether the drug would cause harm when administered to humans’⁹.

Is pentadeca arginate banned in sports?

Yes, as BPC-157, which WADA’s 2026 List bans at all times under class S0¹³. WADA has not ruled on pentadeca arginate by name, but in 2024 an arbitrator banned a US speed skater for a year after the athlete declared taking a supplement whose label listed ‘BPC-157 Arginate Salt’; USADA had charged the athlete with using BPC-157 and DHEA, both of which a laboratory found in the capsules²⁶.

Is there any research on pentadeca arginate?

Very little. PubMed lists no study of it in people or animals, and ClinicalTrials.gov lists no trial that names it³⁶. Its only data are lab and animal experiments described in a 2017 patent that was not peer reviewed, and a 2026 review mentions it in one short passage⁴²¹.

What is still unknown

Which salt, and which ratio of arginine to peptide, do products sold as PDA actually contain? We found no independent test of a product sold as PDA, and the one lab analysis we found of a supplement labeled as BPC-157 arginate salt reported its BPC-157 content, not its salt form.
Did the Zagreb rat studies supplied by Diagen use the arginine salt, as the patent says of its own experiments? The published papers we checked do not name the salt form, and the patent itself says the peptide had until then been used in its free form, as the acetate or as a sodium salt.
Does the arginine salt change how much peptide is absorbed, how long it lasts or what it does in the body? We found no published study that measured this.
What is its half-life? We found no published study that measured it for the salt in animals or people.
Who coined the name ‘pentadeca arginate’, and when were products first sold under it? The earliest clinic page we found is from 31 July 2024.
Has FDA named pentadeca arginate in any warning letter or statement? We found none.
Would a final FDA decision on BPC-157’s free base or acetate affect the arginine salt? FDA says each salt must be evaluated separately.
Is there a USP or NF monograph for any arginine salt of BPC-157? FDA found none for the free base or the acetate; we could not check USP directly.
One clinic page describes ‘Phase I Clinical Development’ for PDA with a safety evaluation ‘ongoing’; we found no registered trial that names PDA.
Which form of BPC-157 did the tablets in a 2015 trial registration (NCT02637284) contain? Its record does not say.
Status in countries other than the US and Australia: not verified.

Sources

1BPC-157 vs. Pentadeca Arginate (PDA): Unlocking the Healing Power of a Revolutionary Peptide American Wellness Pharmacy (vendor), 13 Jan 2026. americanwellnesspharmacy.com (seller page, deliberately not linked)
2Pentadeca Arginate (PDA) | Peptide Science Library | Paragon Sports Medicine Paragon Sports Medicine (clinic), accessed 8 Oct 2026. paragonsportsmedicine.com (seller page, deliberately not linked)
3PubMed search: pentadeca arginate, pentadecapeptide arginate or BPC-157 arginate, or arginate or arginine salt with BPC 157, bepecin or pentadecapeptide (0 results) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
4US 9,850,282 B2: Stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy U.S. Patent and Trademark Office, 26 Dec 2017. image-ppubs.uspto.gov
5Drugs@FDA via openFDA: search for active ingredients named pentadeca, BPC, bepecin or arginate (no matches) U.S. Food and Drug Administration (openFDA), 7 Oct 2026. api.fda.gov · data query
6ClinicalTrials.gov search: pentadeca, pentadecapeptide arginate, or arginate with BPC, bepecin or pentadecapeptide (0 studies) ClinicalTrials.gov, accessed 8 Oct 2026. clinicaltrials.gov
7FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23-24, 2026: BPC-157-related bulk drug substances U.S. Food and Drug Administration, 11 May 2026. fda.gov
8FDA presentations, July 23, 2026, Pharmacy Compounding Advisory Committee meeting U.S. Food and Drug Administration, 23 Jul 2026. fda.gov
9Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration, 22 Apr 2026. fda.gov
10Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
11Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov
12Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327) Federal Register of Legislation, Australian Government, 28 Sep 2026. legislation.gov.au
13World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
14Finnrick public data summary (llms-full.txt, generated 25 September 2026) Finnrick, 25 Sep 2026. finnrick.com
15PDA (Pentadeca Arginate): How It Works & Evidence (2026) The Peptide Catalog, 3 Jun 2026. thepeptidecatalog.com
16Pentadecapeptide Arginate (PDA) · IAM IAM (vendor), 4 Jun 2025. iamhrt.com (seller page, deliberately not linked)
17BPC-157 (UNII 8ED8NXK95P) substance record FDA Global Substance Registration System (GSRS), accessed 8 Oct 2026. precision.fda.gov
18Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats PLoS One, 14 Sep 2016. pubmed.ncbi.nlm.nih.gov
19Pentadeca Arginate: Next-Gen BPC-157 for Healing & Recovery All U Health (vendor), 31 Jul 2024. alluhealth.com (seller page, deliberately not linked)
20PDA Peptide Dosage: What Providers Consider | Vita Bella Health Vita Bella Health (telehealth seller), 7 Oct 2026. vitabella.com (seller page, deliberately not linked)
21Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 1 Jan 2026. pubmed.ncbi.nlm.nih.gov
22World Anti-Doping Code International Standard: Prohibited List 2027 World Anti-Doping Agency, 21 Sep 2026. wada-ama.org
23PEPTIDE-L WAVE! PCAC Approves Four Bulk Drug Substances for the 503A List FDA Law Blog (Hyman, Phelps & McNamara), 24 Jul 2026. thefdalawblog.com
24July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee U.S. Food and Drug Administration, 6 Aug 2026. fda.gov
25PCO-02 - Safety and Pharmacokinetics Trial (NCT02637284) ClinicalTrials.gov, 22 Dec 2015. clinicaltrials.gov
26Final Award of Arbitrator, USADA v. a US short track speed skater (NE ADR Case Number 24062102) U.S. Anti-Doping Agency, 20 Aug 2024. usada.org

Not medical advice. This page reports what studies and regulators say; it does not recommend using any product. How we grade evidence · Report an error.